Galapagos has been granted a patent for antibodies targeting human IL-17C, aimed at treating inflammatory disorders such as atopic dermatitis and psoriasis. The patent details specific amino acid sequences for the antibody regions involved in the therapeutic method. GlobalData’s report on Galapagos gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Galapagos, Peptide pharmacophores was a key innovation area identified from patents. Galapagos's grant share as of June 2024 was 38%. Grant share is based on the ratio of number of grants to total number of patents.
Antibodies for treating inflammatory disorders like psoriasis
The granted patent US11987621B2 outlines a method for treating inflammatory disorders through the administration of specific antibodies or antibody fragments. The claims detail two primary configurations of these antibodies, each defined by distinct heavy and light chain complementarity-determining regions (CDRs) with specified amino acid sequences. The antibodies may be human, humanized, or chimeric, and can be isolated or recombinant. Notably, the antibodies are designed to target human IL-17C, with some claims extending specificity to cynomolgus and mouse IL-17C as well.
Additionally, the patent includes claims for pharmaceutical compositions that incorporate these antibodies or fragments along with a pharmaceutically acceptable carrier or excipient. The sequences referenced in the claims are identified by specific SEQ ID numbers, which provide a precise framework for the development of these therapeutic agents. The methods described aim to provide effective treatment options for subjects suffering from various inflammatory disorders, leveraging the specificity and efficacy of the targeted antibodies.
To know more about GlobalData’s detailed insights on Galapagos, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
